

Received: 02 December 2023 / Accepted: 16 April 2024 / Published online: 30 April 2024

DOI 10.34689/SH.2024.26.2.019

UDC: 616.441-006.6-092-08

## **RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: CLINICOPATHOLOGICAL CHARACTERISTICS, MOLECULAR GENETIC ALTERATIONS. REVIEW.**

**Aidana M. Rakhmankulova**<sup>1</sup>, <https://orcid.org/0000-0003-3307-413X>

**Laura A. Pak**<sup>1</sup>, <https://orcid.org/0000-0002-5249-3359>

**Lyudmila M. Pivina**<sup>1</sup>, <https://orcid.org/0000-0002-8035-4866>

**Sayat Z. Tanatarov**<sup>2</sup>, <https://orcid.org/0000-0001-8958-8768>

**Bayan Zh. Atantayeva**<sup>2</sup>, <https://orcid.org/0009-0003-0004-8354>

**Madina A. Mussulmanova**<sup>1</sup>, <https://orcid.org/0009-0006-5557-3692>

**Saltanat O. Bolsynbekova**<sup>3</sup>, <https://orcid.org/0009-0002-2462-1883>

**Nailya A. Kabildina**<sup>4</sup>, <https://orcid.org/0000-0002-5616-1829>

**Arailym B. Baurzhan**<sup>2</sup>, <https://orcid.org/0000-0003-0279-6607>

<sup>1</sup> NCJSC "Semey Medical University," Semey, the Republic of Kazakhstan;

<sup>2</sup> Nuclear Medicine and Oncology Center, Semey, the Republic of Kazakhstan;

<sup>3</sup> National Scientific Oncological Center, Astana, the Republic of Kazakhstan;

<sup>4</sup> NCJSC "Karaganda Medical University," Karaganda, the Republic of Kazakhstan.

### **Abstract**

**Introduction.** Thyroid cancer is one of the most common endocrine malignancies. Radioactive iodine  $I^{131}$  is the baseline drug in the therapy of patients with differentiated thyroid cancer (DTC); however, 5% to 15% of DTC and 50% of metastatic DTC are not amenable to radioactive iodine  $I^{131}$  therapy. Some patients suffer from recurrent disease after complex treatment. Recurrent disease is often resistant to radioiodine and shows a poor response to radioactive iodine therapy.

**The aim.** To analyze the publications devoted to the problems of radioiodine-resistant thyroid cancer and their clinicopathological and molecular-genetic characteristics.

**Search strategy.** The literature search was performed in the electronic databases Web of Science Core Collection, Scopus, Google Scholar over the past 5 years: from 2018 to 2023. *Inclusion criteria* were systematic reviews, original articles. *Exclusion criteria* were articles of poor methodological quality, duplication, missing or incomplete data in articles, case reports, letters, editorials, and expert opinions. 135 articles were found, of which 88 were selected for analysis.

**Results of the research.** According to the material studied, special attention is now paid to the presence of driver mutations, such as telomerase reverse transcriptase promoter mutations TERT, BRAF V600E, NRAS, which show an aggressive genetic pattern; they can also be used for patient risk stratification when determining radioiodine resistance in patients. In addition, histological examination of the tumor is also one of the most important predictors of DTC prognosis.

**Conclusion.** Based on the analysis of publications, we can conclude that significant progress has been made over the past decades in understanding the molecular mechanisms that cause the malignant evolution of DTC and the development of radioiodine resistance. Given the relationship between molecular and histological heterogeneity, the selection of tumor samples for molecular genetic analysis should be based on the results of histological evaluation of the entire tumor. Comprehensive molecular genetic analysis, as well as histological characteristics of the tumor, will subsequently play an important role in stratifying patients and determining further patient management tactics.

**Keywords:** Well-differentiated thyroid cancer, Radioactive iodine therapy, Radioiodine resistance, BRAF V600E, TERTp, NRAS.

### **Резюме**

## **РАДИОЙОДРЕЗИСТЕНТНЫЙ ДИФФЕРЕНЦИРОВАННЫЙ РАК ЩИТОВИДНОЙ ЖЕЛЕЗЫ: КЛИНИКО-ПАТОЛОГИЧЕСКИЕ ХАРАКТЕРИСТИКИ, МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИЕ АЛЬТЕРАЦИИ. ОБЗОР ЛИТЕРАТУРЫ.**

**Айдана М. Рахманкулова**<sup>1</sup>, <https://orcid.org/0000-0003-3307-413X>

**Лаура А. Пак**<sup>1</sup>, <https://orcid.org/0000-0002-5249-3359>

**Людмила М. Пивина**<sup>1</sup>, <https://orcid.org/0000-0002-8035-4866>

**Саят З. Танатаров**<sup>2</sup>, <https://orcid.org/0000-0001-8958-8768>

**Баян Ж. Атантаева**<sup>2</sup>, <https://orcid.org/0009-0003-0004-8354>

**Мадина А. Мусульманова**<sup>1</sup>, <https://orcid.org/0009-0006-5557-3692>

**Салтанат О. Болсынбекова**<sup>3</sup>, <https://orcid.org/0009-0002-2462-1883>

**Найля А. Кабилдина**<sup>4</sup>, <https://orcid.org/0000-0002-5616-1829>

**Арайлым Б. Бауржан**<sup>2</sup>, <https://orcid.org/0000-0003-0279-6607>

<sup>1</sup> НАО «Медицинский университет Семей», г. Семей, Республика Казахстан;

<sup>2</sup> Центр ядерной медицины и онкологии, г. Семей, Республика Казахстан;

<sup>3</sup> Национальный научный онкологический центр, г. Астана, Республика Казахстан;

<sup>4</sup> НАО «Медицинский университет Караганды», г. Караганда, Республика Казахстан.

**Введение.** Рак щитовидной железы является одним из наиболее распространенных злокачественных новообразований эндокринной системы. Радиоактивный йод <sup>131</sup>I является базисным препаратом в терапии пациентов с дифференцированным раком щитовидной железы (ДРЩЖ); однако от 5% до 15% дифференцированных раков щитовидной железы и 50% метастатических ДРЩЖ не поддаются лечению радиоактивным йодом <sup>131</sup>I. Некоторые пациенты страдают от рецидивов заболеваний после комплексного лечения. Рецидивирующее заболевание часто оказывается устойчивым к радиоактивному йоду и показывает низкий ответ на радиоiodотерапию.

**Цель.** Проанализировать публикации, посвященные проблемам радиоiodрезистентного рака щитовидной железы и их клинико-патологическим и молекулярно-генетическим характеристикам.

**Стратегия поиска.** Поиск литературы был осуществлен в электронных базах Web of Science Core Collection, Scopus, Google Scholar за последние 5 лет: с 2018 по 2023 годы. *Критериями включения* являлись систематические обзоры, оригинальные статьи. *Критериями исключения* являлись статьи низкого методологического качества, случаи дублирования, отсутствия или неполные данные в статьях, отчеты о клинических случаях, письма, редакционные статьи и мнения экспертов. Были найдены 135 статей, из них 88 были выбраны для анализа.

**Результаты исследования.** Согласно изученному материалу, на сегодняшний день особое внимание уделяется наличию драйверных мутации, таких как мутации промотора обратной транскриптазы теломеразы TERT, BRAF V600E, NRAS, которые демонстрируют агрессивную генетическую картину, они также могут быть включены для стратификации риска пациентов в определении радиорезистентности у пациентов. Более того, гистологическое исследование опухоли также является одним из ключевых предикторов прогноза ДРЩЖ.

**Выводы.** Исходя из анализа публикаций, можно сделать вывод, что за последние несколько десятилетий достигнут значительный прогресс в понимании молекулярных механизмов, вызывающих злокачественную эволюцию ДРЩЖ и развитию радиоiodрезистентности. Учитывая связь между молекулярной и гистологической гетерогенностью, отбор образцов опухоли для молекулярно-генетического анализа должен основываться на результатах гистологической оценки всей опухоли. Комплексный молекулярно-генетический анализ, а также гистологическая характеристика опухоли в последующем будет играть важную роль в стратификации пациентов и определении дальнейшей тактики ведения пациента.

**Ключевые слова:** Высокодифференцированный рак щитовидной железы, Радиоiodтерапия, Радиоiodрезистентность, BRAF V600E, TERT, NRAS.

Түйіндеме

## **РАДИОЙОДҚА ТӘЗІМДІ ҚАЛҚАНША БЕЗІНІҢ САРАЛАНҒАН ОБЫРЫ: КЛИНИКО-ПАТОЛОГИЯЛЫҚ СИПАТТАМАЛАРЫ, МОЛЕКУЛЯРЛЫҚ- ГЕНЕТИКАЛЫҚ АЛЬТЕРАЦИЯЛАРЫ. ӘДЕБИ ШОЛУ.**

**Айдана М. Рахманкулова**<sup>1</sup>, <https://orcid.org/0000-0003-3307-413X>

**Лаура А. Пак**<sup>1</sup>, <https://orcid.org/0000-0002-5249-3359>

**Людмила М. Пивина**<sup>1</sup>, <https://orcid.org/0000-0002-8035-4866>

**Саят З. Танатаров**<sup>2</sup>, <https://orcid.org/0000-0001-8958-8768>

**Баян Ж. Атантаева**<sup>2</sup>, <https://orcid.org/0009-0003-0004-8354>

**Мадина А. Мусульманова**<sup>1</sup>, <https://orcid.org/0009-0006-5557-3692>

**Салтанат О. Болсынбекова**<sup>3</sup>, <https://orcid.org/0009-0002-2462-1883>

**Найля А. Кабилдина**<sup>4</sup>, <https://orcid.org/0000-0002-5616-1829>

**Арайлым Б. Бауржан**<sup>2</sup>, <https://orcid.org/0000-0003-0279-6607>

<sup>1</sup> КеАҚ «Семей Медицина Университеті», Семей қ., Қазақстан Республикасы;

<sup>2</sup> Ядролық медицина және онкология орталығы, Семей қ., Қазақстан Республикасы;

<sup>3</sup> Ұлттық ғылыми онкология орталығы, Астана қ., Қазақстан Республикасы;

<sup>4</sup> КеАҚ «Қарағанды Медицина Университеті», Карағанды қ., Қазақстан Республикасы.

**Кіріспе.** Қалқанша безінің қатерлі ісігі - эндокриндік жүйенің ең көп таралған қатерлі ісіктерінің бірі. Радиоактивті йод  $I^{131}$  қалқанша безінің сараланған обыры (ҚБСО) бар науқастарды емдеудегі негізгі препарат болып табылады, алайда, қалқанша безінің сараланған обырының 5%-15% дейін және 50% метастаздық ҚБСО  $I^{131}$  радиоактивті йодпен емдеуге төзімді болып келеді. Кейбір науқастар кешенді емдеуден кейінгі рецидивтерден зардап шегеді. Қайталанатын ауру жиі радиойодқа төзімді болып келеді және радиойодты терапияға нашар жауап береді.

**Мақсаты.** Радиойодқа төзімді қалқанша безінің қатерлі ісігі мәселелеріне және олардың клиничко-патологиялық және молекулалық-генетикалық сипаттамаларына арналған жарияланымдарды талдау.

**Іздеу стратегиясы.** Әдебиеттерді іздеу Web of Science Core Collection, Scopus, Google Scholar электронды базаларында соңғы 5 жылдың ішіндегі: 2018 жыл мен 2023 жылдар аралығында жүргізілді. Қосылу критерийлеріне жүйелі шолулар, түпнұсқа мақалалар енгізілді. Алып тастау критерийлеріне әдістемелік сапасы төмен мақалалар, мақалалардағы деректердің қайталануы, жетіспейтін немесе толық емес деректері, жағдайлық есептер, хаттар, редакциялық мақалалар және сараптамалық қорытындылар кірді. 135 мақала табылып, оның 88-і талдауға іріктеліп алынды.

**Зерттеу нәтижелері.** Зерттеу нәтижесі гистологиялық, Ki-67 LI экспрессиясының иммуногистохимиялық (ИГХ) зерттеулерін жүргізу радиойодқа төзімді қалқанша безінің сараланған қатерлі ісігінде маңызды болжамы болып табылатынын көрсетті. Сондай-ақ BRAFV600E/TERTp, BRAFV600E/NRAS драйверлік мутацияларының қатар кездесуі агрессивті клиничко-патологиялық сипаттамалармен және радиойодқа төзімділіктің пайда болуымен байланысты болуы мүмкін, бұл өз кезегінде емдеу тактикасын анықтауда маңызды болып табылады.

**Қорытынды.** Қорытындылай келе, радиойодқа төзімді қалқанша безінің қатерлі ісігінің клиничко-патологиялық және молекулалық сипаттамаларын анықтау үшін гистологиялық, Ki-67 LI экспрессиясының иммуногистохимиялық (ИГХ) зерттеулерін жүргізу, сондай-ақ TERTp, BRAFV600E, NRAS мутацияларына молекулалық-генетикалық зерттеу жүргізу қажет. Бұл көрсеткіштерді одан әрі зерттеу өзекті мәселе болып табылады және қосымша зерттеулерді қажет етеді.

**Түйінді сөздер.** «жоғары сараланған қалқанша безінің қатерлі ісігі», «радиойодты терапия», «радиойодқа төзімділік», «BRAFV600E», «TERT», «NRAS».

#### For citation:

Rakhmankulova A.M., Pak L.A., Pivina L.M., Tanatarov S.Z., Atantayeva B.Zh., Mussulmanova M.A., Bolsynbekova S.O., Kabildina N.A., Baurzhan A.B. Radioiodine-resistant differentiated thyroid cancer: clinicopathological characteristics, molecular genetic alterations. Review // *Nauka i Zdravookhranenie* [Science & Healthcare]. 2024. Vol.26 (2), pp. 158-170. doi 10.34689/SH.2024.26.2.019

Рахманкулова А.М., Пак Л.А., Пивина Л.М., Танатаров С.З., Атантаева Б.Ж., Мусульманова М.А., Болсынбекова С.О., Кабилдина Н.А., Бауржан А.Б. Радиойодрезистентный дифференцированный рак щитовидной железы: клиничко-патологические характеристики, молекулярно-генетические альтерации. Обзор литературы // *Наука и Здравоохранение*. 2024. Т.26 (2). С. 158-170. doi 10.34689/SH.2024.26.2.019

Рахманкулова А.М., Пак Л.А., Пивина Л.М., Танатаров С.З., Атантаева Б.Ж., Мусульманова М.А., Болсынбекова С.О., Кабилдина Н.А., Бауржан А.Б. Радиойодқа төзімді қалқанша безінің сараланған обыры: клиничко-патологиялық сипаттамалары, молекулалық-генетикалық альтерациялары. Әдеби шолу // *Ғылым және Денсаулық сақтау*. 2024. Т.26 (2). Б. 158-170. doi 10.34689/SH.2024.26.2.019

#### Introduction

In recent decades, thyroid cancer (TC) has become a serious public health problem [60]. In terms of growth rate, thyroid cancer outpaces other malignant neoplasms. This trend is not solely attributed to a rise in the number of patients affected by this condition, but also to advancements in diagnostic tools that facilitate the early identification of malignant growths and follicular abnormalities [6]. According to the latest global malignant neoplasm statistics from the International Agency for Research on Cancer (GLOBOCAN 2020), thyroid cancer is the ninth most common malignancy worldwide and its incidence continues to increase, with 586,000 new cases reported in 2020. To date, the highest incidence rates are found in North America, Australia/New Zealand, East Asia and Southern Europe in both sexes, and in Micronesia/Polynesia and South America are often found in females [60].

According to the figures of the Oncological Service of the Republic of Kazakhstan for 2022, thyroid cancer is included in the list of the ten most frequent localizations of cancer in women in 2022. Thyroid cancer moved up from 11th to 9th place, which shows the growth of this disease among women compared to men. The structure of oncopathological incidence in the Republic of Kazakhstan by gender in 2022 is presented in Figure 1 (Figure 1).

The increase in the incidence of malignant neoplasms for 2022 was recorded for all nosologies in general, including malignant neoplasm of the thyroid gland increased from 3.4 to 4.3, that is roughly +26.5%.

Well differentiated thyroid cancer (WDTC), which has a favorable course, is usually treated surgically, i.e. complete thyroidectomy followed by radioiodine therapy and thyroid hormones that suppress thyroid hormone levels.




Figure 1. Structure of oncopathological morbidity in the Republic of Kazakhstan by sex in 2022.

(Taken from the report of the Kazakh Research Institute of Oncology and Radiology: "Indicators of the Oncology Service of the Republic of Kazakhstan for 2022" translated from Russian into English.)

Radioactive iodine <sup>131</sup>I is the baseline drug in the therapy of patients with differentiated thyroid cancer (DTC). Nevertheless, 5% to 15% of differentiated thyroid cancer and 50% of metastatic DTC are not amenable to <sup>131</sup>I treatment. Some patients suffer from recurrent disease after significant treatment. This kind of disease is often resistant to radioiodine and shows a poor response to Radioactive iodine therapy.

Although most of the patients with WDTC have no evidence of disease with appropriate early treatment, recurrence develops in 20-40% of patients. During tumor progression, Radioactive iodine therapy is the first line of treatment. However, up to 5% of thyroid cancer metastases may lose the ability to concentrate iodine and this is called radioiodine resistance disease (RRD); this phenomenon is responsible for a large number of thyroid cancer-related deaths [3].

**The aim:** To analyze publications devoted to the problems of radioiodine-resistant thyroid cancer and their clinicopathological and molecular-genetic characteristics.

**Search strategy.** The literature search was performed in the electronic databases PubMed, WoS, Scopus, Google

Scholar over the past 5 years: from 2018 to 2023. Several sources do not fall into the specified depth, but were accepted for analysis because they contain conceptual information. *Inclusion criteria* were systematic reviews, original articles, literature reviews of peer-reviewed publications. *Exclusion criteria* were articles of poor methodological quality, duplication, missing or incomplete data in articles, case reports, letters, editorials, and expert opinions. From the remaining articles, a plan was formed to write a literature review according to the following sequence: «Radioactive iodine therapy», «The problem of occurrence of radioiodine-resistant well-differentiated thyroid cancer», «Clinicopathological characteristics of radioiodine-resistant thyroid cancer», «Molecular genetic alterations in radioiodine-resistant thyroid cancer». The search was performed by keywords like "well-differentiated thyroid cancer," "Radioactive iodine therapy," "radioiodine resistance," "BRAF V600E," "TERT," and "NRAS." According to the topic, depth of research and keywords, 135 articles were found, of which 88 were selected for review. The source selection algorithm is presented in Figure 2.




Figure 2. Article selection algorithm.

**Results of the study.**

**Radioactive iodine therapy.**

Treatment with radioiodine therapy is based on the selective accumulation of radioactive iodine I131 in thyroid

cells or tumor tissue of differentiated thyroid cancer. Radioactive iodine has a damaging effect on β-particles resulting from the decay of I131 [8,13]. In order to monitor the localization of the isotope within the body, whole-body

planar scintigraphy or single photon emission computed tomography uses  $\gamma$ -rays [10]. The radiopharmaceutical used for RAI is an isotonic solution of  $\text{Na I}^{131}$ , pH about 6-7, or as capsules with  $\text{Na I}^{131}$  lyophilisate.  $\text{I}^{131}$  almost 100% is resorbed from the gastrointestinal tract, thyroid tissue is capable of accumulating up to 80% of orally administrated activity, depending on its functional state [49]. Iodine, in the form of various compound forms, can penetrate through the intestine into the bloodstream, ultimately being transported to the thyroid tissue via the blood current [5]. Radioiodine therapy is made possible by the selective uptake of iodine by thyroid cells, resulting in a concentration of  $\text{I}^{131}$  in the thyroid gland that is significantly higher than in the blood [86]. This selective uptake is facilitated by the sodium iodide symporter. It is a membrane glycoprotein that actively transports  $\text{I}^{131}$  from the blood into the follicular epithelium of the thyroid gland [5,37].

Radioiodine therapy allows you to destroy the remnants of thyroid tissue and possible areas of residual tumor that accumulate radioiodine. This treatment has a positive effect on metastases of differentiated thyroid cancer. The use of specialized treatment reduces the risk of relapse and improves long-term results of therapy [6,42].

Radioiodine ablation is a postoperative course aimed at destroying residual thyroid tissue. Use as adjuvant therapy makes it possible to identify distant metastatic foci in the early stages [10].

Recommendations for the use of radioiodine therapy are based on an assessment of the postoperative risk of relapse and persistence of the disease. Also, according to these recommendations, patients can be constantly monitored [32,87]. For this, oncologists are based on the recommendations of various world societies. Recommendations provided by the European Society of Medical Oncology (ESMO; 2019), National Comprehensive Cancer Network (NCCN; 2022), Society of Nuclear Medicine and Molecular Imaging/European Association of Nuclear Medicine (SNMMI/EANM; 2022). and Society of Nuclear Medicine and Molecular Imaging/European Association of Nuclear Medicine (SNMMI/EANM; 2022) [33].

It is important to note that there are several options for using radioactive iodine in the treatment of differentiated thyroid cancer. Radioiodine ablation and radioiodine therapy are used as treatment for residual disease. In addition, radioiodine therapy is used to destroy distant metastases and for persistent thyroid disease [27]. These treatment options differ in the amount of therapeutic activity of  $\text{I}^{131}$  [11].

Papillary thyroid cancer and follicular thyroid cancer are collectively characterized as differentiated thyroid cancer. These histological types of cancer account for more than 90% of all malignant neoplasms of the thyroid gland [31]. Most cases of thyroid cancer are successfully treated with thyroidectomy, selective radioiodine therapy, and thyroid hormone suppression therapy. When these types of treatments are used in combination, they help patients have a good prognosis for their disease in the future [8].

The incidence of distant metastases at diagnosis is known to be less than 5% in thyroid cancer. Relapses account for approximately 15% of cases during the course

of the disease. It should be noted that relapses or metastases can lead to death from thyroid cancer [68]. In these cases, radioactive iodine  $\text{I}^{131}$  (RAI) is the standard initial therapy for recurrent or metastatic thyroid cancer. Patients treated with radioiodine therapy and whose whole body scintigraphy was negative after therapy showed improved survival rates. The 10-year survival rate and quality of life of such patients reached 92%. However, for some patients, radioiodine therapy is not effective. It is expressed by a decrease in iodine absorption by thyroid cells. It should be noted that the 10-year survival rate in patients resistant to radioiodine therapy decreases to 10–29% [61].

#### **The problem of radioiodine resistance in well-differentiated thyroid cancer.**

Most patients with differentiated thyroid cancer (DTC) are successfully treated with surgery and radioactive iodine. However, some patients with thyroid cancer may experience less favorable treatment outcomes. In these situations, individual treatment approaches are used [46,11]. Postoperative radioactive iodine therapy is used to remove residual thyroid issue [5], eliminate suspected micrometastases or known advanced disease [75].

Radioiodine therapy is based on the expression of the sodium iodide symporter (NIS). This transmembrane protein is located on the plasma membrane of both normal and tumor epithelial cells of the thyroid gland. The NIS transports two sodium ions and one iodine ion into the cytosol. The iodide is then processed by iodine in the thyroid cells [34]. The above glycoprotein may affect the effectiveness of radioiodine treatment. Thus, the sodium iodide symporter may play a significant role in the development of radioiodine resistance. On the one hand, some patients experience remission after one or more courses of radioiodine therapy; on the other hand, other patients develop radioiodine resistance. This is because some patients may have multiple or macrometastases, along with less differentiated tumor status. In this situation, the disease may have a worse prognosis [77,23].

The process of dedifferentiation involves the reduction or disappearance of NIS expression. During the course, the direction of the transmembrane protein changes to the plasma membrane, where NIS functions optimally. This change leads to a decrease in the ability of thyroid cells to absorb iodine [16,19].

A long term study showed that the 10 and 15 year survival rates of patients without any radioiodine administration were much lower than those of patients receiving radioiodine. It should be taken into account that some patients develop radioiodine resistance even with the most appropriate administration of RAI [73]. This significantly worsens the prognosis: the life expectancy of patients with radioiodine refractory differentiated thyroid cancer is 2.5-3.5 years from the moment of diagnosis [43]. Although DTC is often curable by surgery, with or without radioiodine therapy, approximately two-thirds of patients with relapse or metastases develop radioiodine-resistant DTC, which usually has a poor prognosis [86]. The most frequent forms of refractory thyroid cancer in RAI (RAIR-DTC) are PTC, followed by low-differentiated thyroid carcinoma [41]. Despite the fact that PTC has an indolent character and good prognosis in some patients with PTC (5–10%) develops aggressive metastatic disease and resistance

to radioiodine therapy [52]. There are some aggressive subtypes of thyroid cancer. These include tall cell, columnar cell, diffuse sclerosing and spinous nail variants. These variants were associated with higher rates of extrathyroidal spread, multifocality, nodal and distant metastases. Moreover, they are more likely to relapse and are resistant to radioiodine therapy [53,65,66].

Currently, the following criteria are generally used to define tumor radioiodine resistance [19,72]:

- Absence or a progressive decline in radioactive iodine uptake during a whole-body scan after treatment;
- Absence of radioiodine uptake in primary regional recurrence or distant metastases without radioiodine uptake during whole body scan after treatment;
- Structural tumor progression 12-16 months after radioactive iodine therapy despite the presence of iodine in the post-therapy scan;
- Presence of tumor in patients who have received radioiodine therapy with an activity of 600 millicuries (mCi)/22.2 gigabecquerel (GBq) or more, but without evidence of remission;
- Inconsistency between I131 and 18F-FDG accumulation, i.e. there is a negative result on SPECT/CT with radioactive iodine, while a positive result on PET-CT with 18F-FDG.

The presence of the above criteria predicts the likelihood of a tumor being resistant to radioiodine therapy and should be used together for tumor risk stratification in resistance assessment [57]. However, today special attention is paid to the presence of driver mutations, such as pTERT, BRAF V600E, NRAS. These types of mutations demonstrate an aggressive genetic pattern. They can also be used in patient risk stratification to determine treatment tactics [10, 39].

#### **Clinicopathological characteristics of radioiodine-resistant thyroid cancer.**

The clinicopathological characteristics of thyroid cancer are based on the international histological classification of cancer, which is presented by the World Health Organization and updated [12,13]. Until now, pathohistologists relied on the 2017 classifications when making a thyroid diagnosis [85,87]. Still, it should be emphasized that in 2022, the World Health Organization (WHO) released the latest updated fifth edition of the histological classification of thyroid neoplasms in 2022 [38].

The classification system divides thyroid cancer of follicular origin into four categories. The main histological variants are differentiated thyroid cancer, including predominantly papillary thyroid cancer and follicular thyroid cancer. There is also oncocyctic cancer; high-grade carcinomas, including poorly differentiated thyroid cancer and anaplastic thyroid cancer [7].

Modern histological classification is developed on the basis of clinical histopathology and molecular pathogenesis. Most encapsulated or confined thyroid tumors with a predominant follicular growth pattern exhibit a RAS-like molecular profile [37]. Conversely, most thyroid tumors with BRAF V600E-like thyroid cancer and RAS-like thyroid cancer may acquire additional genetic alterations. Subsequently, these histological types can progress to high-grade malignant neoplasms [20].

Currently, histological examination of the tumor is an important predictor of prognosis. In cases where there are Hurthle cells and low-grade thyroid cancer, there is a higher likelihood of developing radioiodine resistance. It should also be noted that histological variants of tumor cells in patients with primary lesions and metastases may become less differentiated during treatment with I131 [47].

In addition, it has been discovered that the classic and follicular variants of papillary thyroid cancer are less aggressive histological subtypes. Conversely, high-cell variant of papillary thyroid cancer, sclerosing diffuse papillary thyroid cancer, hobnail variant, Hurthle cell variant papillary thyroid cancer, and poorly differentiated thyroid cancer are considered such as high-risk histological groups [47]. Therefore, it can be stated that histological subtypes of thyroid cancer are predictors in determining radioiodine resistance [18].

Oncocyctic cell tumors are a unique category of thyroid tumors at the genetic and genomic levels. In clinical settings, oncocyctic cell carcinomas tend not to absorb radioiodine and often spread to lymph nodes. They also have a higher likelihood of developing into anaplastic thyroid cancer compared to other thyroid cancer types, with some cases showing elevated overall mortality and morbidity rates [58].

Updated World Health Organization (WHO) classification provides a clearer comprehension of the cell origins, pathological characteristics (histopathology), molecular categorization and biological behavior of thyroid cancer [14,17].

#### **Molecular and genetic alterations in radioiodine-resistant thyroid cancer.**

To date, a number of main factors for the development of refractory thyroid cancer in RAI have been identified. These include the presence of mutations of the BRAF, PTEN, APC, DICER1, MNG, NRAS, KRAS, TERT family, etc. This can also include exposure to ionizing radiation, hereditary syndromes (Gardner), Cowden, multiple endocrine neoplasia types 2A and 2B, etc.) [47,76]. Mutations or rearrangements of certain genes as well as abnormal expression of molecules in certain signaling pathways are common causes of worsening of DTC.

Over the past few decades, significant progress has been made in understanding the molecular mechanisms causing the malignant evolution of DTC and the transition to resistance to RAI. Iodine can accumulate specifically in thyroid tissue under physiological conditions, which is attributed to sodium iodide symporter (NIS)-mediated iodine uptake localized in the basolateral cell membrane [82,25,84]. One of the hallmarks of dedifferentiation is impaired Na/I symporter (NIS) function [5,55,74]. RAI penetrates the cells through the NIS and emits beta particles that destroy the follicular cell [53].

Unfortunately, some patients experience an initial or gradual loss of iodine uptake and even a decrease in plasma membrane sodium iodide symporter expression. This process indicates a dedifferentiation status known as radioiodine-resistant differentiated thyroid cancer (RAIR-DTC) [67,46]. Radioiodine-resistant cancer cells arise from loss of thyroid differentiation, including iodine uptake and organization. This loss of differentiation is associated with the level of mitogen-activated protein kinase (MAPK) activation. High levels of

such activation are observed in tumors with BRAF (B-raf proto-oncogene) mutations or RAS mutations [48].

The MAPK signaling pathway is often constantly activated across various histological subtypes. The key proteins and major players in this pathway include RAS, RAF, MEK, and ERK, which participate in various cellular processes such as differentiation, proliferation, and apoptosis [59,40]. Thyroid cancer often becomes RAI-R by co-opting RAF and RAS signaling, thereby suppressing NIS and RAI uptake [71]. Genetic and epigenetic changes in the above signaling pathways due to acquired point mutations, chromosomal rearrangements, or aberrant gene mutations underlie decreased NIS signaling. In turn, they are a central factor in the refractoriness of RAI [54,80].

Gene alterations in DTC include point mutations, gene translocations, chimeric fusions, gene amplifications and deletions [50]. In addition, a comprehensive molecular analysis of the primary tumor under the guidance of histological analysis may help to better stratify patients to determine treatment tactics. Given the relationship between molecular and histological heterogeneity, tumor sampling for molecular analysis should be based on a thorough histological evaluation of the entire tumor [22,24].

The clinical significance of BRAFV600E is directly related to the fact that its presence unequivocally indicates the malignant nature of a thyroid neoplasm [1,69]. The BRAFV600E mutation in PTC is strictly specific, with an incidence of 40-70% [29,79]. Also, BRAFV600E correlates with a more aggressive phenotype and higher clinical tumor stage [70,56].

Rumyantsev P.O., Nikiforovich P.A. and co-authors [9] in their study indicated that BRAF V600E has prognostic value, increasing the probability of relapse of PTC. It is reported that the presence of BRAFV600E mutation is a prognostically unfavorable factor increasing the probability of tumor foci resistance to radioactive iodine therapy, which should be taken into account when choosing the tactics of patient management [62]. It should also be noted that in 2015 the clinical guidelines of the American Thyroid Association (ATA) described BRAFV600E and TERT mutations as unfavorable factors of clinical prognosis. Mutations of the TERT promoter are involved in the suppression of *slc5a5* mRNA in RAI-R-DTC. It is suggested that TERT mutations, reduce NIS protein expression and its location in cell membranes. The expression of *slc5a5* mRNA has a greater association with DTC aggressiveness and prognostic features than NIS protein expression detected by immunohistochemical analysis [62].

Liu X., Qu S. *et al.* [45] conducted a study to detect the prevalence of TERT promoter mutation (C228T and C250T) and determined its association with BRAFV600E mutation. The authors examined postoperative paraffin blocks of thyroid tumors: of which 44 cases were benign tumors, 22 cases of classical follicular cancer and 408 cases of papillary cancer from five regions in China. The result showed that no TERT p mutation was found in any of the 44 benign tumors. C228 mutation was much more common than C250 T mutation in both PTC and FTC. The C228T mutation was found in 9.6% of cases (39 of 408) of PTCs and C250T was found in 1.7% (7 of 408) of PTC. Together, the two mutations were found in 11.3% (46 of 408) of PTC. In follicular thyroid cancer, C228T was found in 31.8% (7 of

22) and C250T in 4.6% (1 of 22) of samples, and together they were found in 36.4% (8 of 22) of PTC. The authors of this study concluded that, in general, TERT p. mutations were associated with aggressive clinicopathological characteristics of PTC [21]. Also, the results illustrated that the coexistence of BRAF and TERT mutations were associated with aggressive clinical and pathological behavior of PTC [42]. Molecular analyses provide useful information on the role of predicting the occurrence of radioiodine-resistant PTC [47].

Liu X, Bishop J. *et al.* [44] investigated the effects of BRAF V600E or TERT promoter mutations and their coexistence on the clinicopathological outcomes of PTC from 421 thyroid tissue samples: of these, 85 were benign opxcholes, 257 PTC, and 79 FTC. Two mutations were detected in 11 of 12 (91,7%) thyroid cancer cell lines. The C228T mutation was found in 0 of 85 (0,0%) benign thyroid tumors, in 30 of 257 (11,7%) PTC, in 9 of 79 (11,4%) FTC, in 3 of 8 (37,5%) PTC, and in 23 of 54 (42,6%). The C250T mutation was absent in the PTC sample but was detected in two FTC cell lines, as well as two anaplastic thyroid cancer (ATC) cell lines. Both two TERT promoter mutations found to be exclusive of each other in both thyroid cancer cell lines and tumor samples. Altogether, they were identified in 11 of 79 (13.9%) FTC, 25 of 54 (46,3%) ATC and 7 of 7 (100%) ATC samples. The TERT promoter mutations was not observed in 16 MTC samples. In three cases, PTC and ATC were located in the same thyroid gland, and in each case both PTC and ATC contained the C228T mutation. In their study, the authors concluded that a large proportion of PTC samples positive for TERT promoter mutations contained the BRAF V600E mutation. This means that it is possible that BRAFV600E mutations, together with TERTp, are associated with greater aggressiveness of thyroid cancer. Possible mechanisms for the connection between genetic mutations and the development of radioiodine resistance were also discovered. However, it is worth noting that a connection between these two types of mutations could not be established [29].

The significance of BRAF, TERT p and RAS mutations as prognostic biomarkers has been evaluated in a number of studies [63]. BRAF mutations are associated with markers of clinical aggressiveness (larger tumors, older age, extra-thyroidal spread and LNM) and poor clinical outcome, although the latter association depends on additional clinicopathological features [70]. BRAF mutations are also associated with decreased expression of the sodium iodide symporter, a crucial determinant of response to radioiodine therapy [57]. Although few data are currently available on the clinical significance of TERT p mutations, current publications report an association between the presence of this mutation and clinically aggressive disease, including resistance to radioiodine [81]. Analysis of molecular markers including BRAFV600E and the p-TERT, C228T and C250T mutations have been proposed as reliable prognostic biomarkers and have been reported to be associated with aggressive clinical and pathological characteristics, making the study of these biomarkers a new area of cancer research [24].

However, the coexistence of TERT promoter mutation and BRAFV600E have a marked synergistic effect on the aggressiveness of PTC, including increased tumor

recurrence, high patient mortality and resistance to radioiodine therapy, while either mutation individually has been reported to show less significant effects. In adult patients (>55 years), the disease tends to progress more rapidly and the tumor behaves more aggressively than in younger individuals [89].

Huang M, Yan C. and co-authors [35] conducted a study in northwest China, where 483 patients were included. Of these, 435 (90.1%) patients with PTC had BRAF V600E mutation, 419 patients had BRAF V600E mutation alone and 16 patients had double mutations. Forty-eight patients had triple negative mutations. The authors concluded that the prevalence of the BRAF V600E mutation was higher in northwest China. The authors also note that the coexistence of the BRAF V600E and TERT p mutations was significantly correlated with lymph node metastases and multifocality. Patients with these mutations are more likely to have distant metastases and tumor relapses. The presence of a double mutation results in tumor spread beyond the thyroid gland and may result in disease-related death [35].

RAS mutation is a classical activator of the MAPK pathway and the phosphatidylinositol-3-kinase (PI3K) pathway. RAS genes including NRAS, HRAS and KRAS are called proto-oncogenes. RAS mutation is closely associated with distant metastasis and other clinical adverse reactions of thyroid cancer. Among them, mutation in NRAS codon 61 is the most common, in addition to HRAS codon 61, KRAS codon 12/13, KRAS codon 61 and other mutations. RAS mutation has been found to coexist with BRAF mutation and RET/PTC rearrangement, especially in advanced stages of papillary TC, and it is an important factor for unfavourable prognosis [36].

Leila Shobab, Cristiane Gomes-Lima et al. retrospectively analyzed the data of patients with CRC followed up during 2013-2017 in two centers. Patients were considered refractory to radioiodine according to the American Thyroid Association guidelines. The control group was comparable in gender and age and had either regression or stabilization of disease (according to response evaluation criteria for solid tumors) at follow-up for at least three years after initial therapy. The molecular profiles of a subset of patients with radioiodine resistance were reviewed. Molecular profiling data in the radioiodine resistance subgroup showed that 50% of patients had mutations in the RAS/RAF pathway. The authors also noted that among patients with metastatic differentiated thyroid cancer, patients with radioiodine resistance had similar histopathological and clinical characteristics to patients with avid thyroid cancer. The risk of radioiodine refractoriness increases at age  $\geq 46$  years and decreases in Caucasian race [30].

**Conclusion.** Based on the analysis of publications, we can conclude that significant progress has been made over the past decades in understanding the molecular mechanisms that cause the malignant evolution of DTC and the development of radioiodine resistance. Given the relationship between molecular and histological heterogeneity, the selection of tumor samples for molecular genetic analysis should be based on the results of histological evaluation of the entire tumor. Comprehensive molecular genetic analysis, as well as histological

characteristics of the tumor, will subsequently play an important role in stratifying patients and determining further patient management tactics.

**Funding** – none;

**Conflict of interest** – none;

**Literature:**

1. Абдрашимова А.Т., Панова Т.Н., Дьякова О.Н., Джувалыков С.Г., Теплый Д.Л. Подходы к ранней диагностике рака щитовидной железы // Кубанский научный медицинский вестник. 2018. 25(3):139–148.

2. Амиров Э.В., Федоров В.Э., Захохов Р.М. Результаты хирургического лечения узловых образований щитовидной железы у женщин репродуктивного возраста // Медицинский альманах. 2013. №6 (30). С. 184-186.

3. Бельцевич Д.Г., Мудунов А.М., Ванушко В.Э., Румянцев П.О., Мельниченко Г.А., Кузнецов Н.С., Подвязников С.О., Алымов Ю.В. и др. Дифференцированный рак щитовидной железы // Современная онкология. 2020. Т. 22. №4. С. 30-44. doi:10.26442/18151434.2020.4.200507

4. Бородавина Е. В. и др. Исторические аспекты и современные концепции в лечении больных дифференцированным раком щитовидной железы, рефрактерным к терапии радиоактивным йодом // Опухоли головы и шеи. 2021. Т. 11. №. 4. С. 119-130.

5. Гарипов К. А., Афанасьева З. А., Гафиуллина А. Д. Роль апоптоза в формировании радиорезистентности при дифференцированном раке щитовидной железы // Вестник Авиценны. – 2020. – Т. 22. – №. 2. – С. 301-310.

6. Денисенко Н.П. и др. Генетические маркеры, ассоциированные с резистентностью к радиойодтерапии, у больных раком щитовидной железы // Современная онкология. 2022. Т. 24. №.3. С. 345-350.

7. Понкина О.Н. Классификация опухолей щитовидной железы (ВОЗ, 2017): Акцент на прогноз // Инновационная медицина Кубани. 2017. Т. 8. №.4. С. 53-59.

8. Ромащенко П.Н. и др. Молекулярно-генетические исследования в хирургии щитовидной железы // Таврический медико-биологический вестник. 2021. Т. 24. №. 2. С. 118-126.

9. Румянцев П.О. и др. Мутация BRAFV600E при папиллярном раке щитовидной железы. Клинические и методологические аспекты // Вопросы онкологии. 2019. Т. 65. №. 1. С. 16-26.

10. Шуринов А.Ю., Крылов В.В., Бородавина Е.В. Радиойодабляция при раке щитовидной железы. Исторические и современные аспекты. Обзор литературы // Онкологический журнал: лучевая диагностика, лучевая терапия. 2021. Т. 4. №. 4. С.9-19.

11. Шуринов А. Ю., Бородавина Е.В. Динамический контроль после радиойодабляции при дифференцированном раке щитовидной железы: взгляд радиолога // Опухоли головы и шеи. 2023. Т. 13. №. 1. С. 91-101.

12. Aashiq M., Silverman D.A., Na'ara S., Takahashi H., Amit M. Radioiodine-Refractory Thyroid Cancer: Molecular Basis of Redifferentiation Therapies, Management, and Novel Therapies. *Cancers* (Basel). 2019 Sep 17. 11(9):1382. doi: 10.3390/cancers11091382. PMID: 31533238. PMCID: PMC6770909.



13. Ahuja S., Avram A.M., Dillehay G., Greenspan B.S., Gulec S., Van Nostrand D. The Martinique Principles. *J Nucl Med.* 2019 Sep. 60(9):1334-1335. doi: 10.2967/jnumed.119.232066. Epub 2019 Jun 21. PMID: 31227575.
14. Bai Y., Kakudo K., Jung C.K. Updates in the Pathologic Classification of Thyroid Neoplasms: A Review of the World Health Organization Classification. *Endocrinol Metab.* 2020. 35(4):696-715.
15. Chandekar KR, Satapathy S, Bal C. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis. *Clin Endocrinol (Oxf).* 2024 Feb;100(2):181-191. doi: 10.1111/cen.15001. Epub 2023 Dec 4. PMID: 38050454.
16. Mete O. Special Issue On the 2022 WHO Classification of Endocrine and Neuroendocrine Tumors: a New Primer for Endocrine Pathology Practice // *Endocr Pathol.* 2022 Mar. 33(1):1-2. doi: 10.1007/s12022-022-09712-6. PMID: 35246804; PMCID: PMC8896415.
17. Baloch Z.W., Asa S.L., Barletta J.A., Ghossein R.A., Juhlin C.C., Jung C.K., LiVolsi V.A., Papotti M.G., Sobrinho-Simões M., Tallini G., Mete O. Overview of the 2022 WHO Classification of Thyroid Neoplasms. *Endocr Pathol.* 2022 Mar. 33(1):27-63. doi: 10.1007/s12022-022-09707-3. Epub 2022 Mar 14. PMID: 35288841.
18. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. *Nature Reviews Cancer.* 2008. T. 8. №. 8. C. 592-603.
19. Buffet C., Wassermann J., Hecht F., Leenhardt L., Dupuy C., Groussin L., Lussey-Lepoutre C. Redifferentiation of radioiodine-refractory thyroid cancers. *Endocr Relat Cancer.* 2020 May. 27(5):R113-R132. doi: 10.1530/ERC-19-0491. PMID: 32191916.
20. Capdevila J., Galofré J.C., Grande E., Zafón Llopis C., Ramón Y., Cajal Asensio T., Navarro González E., Jiménez-Fonseca P., Santamaría Sandi J., Gómez Sáez J.M., Riesco Eizaguirre G. Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI). *Clin Transl Oncol.* 2017 Mar;19(3):279-287. doi: 10.1007/s12094-016-1554-5. Epub 2016 Oct 4. PMID: 27704399.
21. Chen L., Luo Q., Shen Y., Yu Y., Yuan Z., Lu H., Zhu R. Incremental value of <sup>131</sup>I SPECT/CT in the management of patients with differentiated thyroid carcinoma. *J Nucl Med.* 2008 Dec;49(12):1952-7. doi: 10.2967/jnumed.108.052399. Epub 2008 Nov 7. PMID: 18997044.
22. Chung J.H. BRAF and TERT promoter mutations: clinical application in thyroid cancer. *Endocr J.* 2020 Jun 29;67(6):577-584. doi: 10.1507/endocr.EJ20-0063. Epub 2020 Apr 21. PMID: 32321884.
23. Cook F.A., Cook S.J. Inhibition of RAF dimers: it takes two to tango. *Biochem Soc Trans.* 2021 Feb 26;49(1):237-251. doi: 10.1042/BST20200485. PMID: 33367512; PMCID: PMC7924995.
24. Deandreis D., Rubino C., Tala H., Leboulleux S., Terroir M., Baudin E., Larson S., Fagin J.A., Schlumberger M., Tuttle R.M. Comparison of Empiric Versus Whole-Body/Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. *J Nucl Med.* 2017 May;58(5):717-722. doi: 10.2967/jnumed.116.179606. Epub 2016 Oct 13. PMID: 27738010.
25. Eftychia G.K., Roupas N.D., Markou K.B. Effect of excess iodine intake on thyroid on human health // *Minerva Med.* 2017. T.108. №.2. C. 136-146.
26. Eszlinger M., Khalil M., Gillmor A.H., Huang H., Stewardson P., McIntyre J.B., Morrissy S., Paschke R. Histology-based molecular profiling improves mutation detection for advanced thyroid cancer. *Genes Chromosomes Cancer.* 2021 Aug;60(8):531-545. doi: 10.1002/gcc.22949. Epub 2021 Mar 31. PMID: 33749950.
27. Fagin J.A., Wells S.A. Jr. Biologic and Clinical Perspectives on Thyroid Cancer. *N Engl J Med.* 2016 Sep 15;375(11):1054-67. doi: 10.1056/NEJMra1501993. PMID: 27626519; PMCID: PMC5512163.
28. Ferlay J., Colombet M., Soerjomataram I., Mathers C., Parkin D.M., Piñeros M., Znaor A., Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int J Cancer.* 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6. PMID: 30350310.
29. Filetti S., Durante C., Hartl D., Leboulleux S., Locati L.D., Newbold K., Papotti M.G., Berruti A. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol.* 2019 Dec 1;30(12):1856-1883. doi: 10.1093/annonc/mdz400. PMID: 31549998.
30. Forbes S.A., Beare D., Gunasekaran P., Leung K., Bindal N., Boutselakis H., Ding M., Bamford S., et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. *Nucleic Acids Res.* 2015 Jan;43 (Database issue): D805-11. doi: 10.1093/nar/gku1075. Epub 2014 Oct 29. PMID: 25355519; PMCID: PMC4383913.
31. Fukuda N., Takahashi S. Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. *Cancers (Basel).* 2021 May 10;13(9):2279. PMID: 34068664; PMCID: PMC8126102
32. Gruber J.J., Colevas A.D. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. *Oncologist.* 2015 Feb;20(2):113-26. doi: 10.1634/theoncologist.2014-0313. Epub 2015 Jan 23. PMID: 25616432; PMCID: PMC4319630.
33. Gulec S.A., Ahuja S., Avram A.M., Bernet V.J., Bourguet P., Draganescu C., Elisei R., Giovanella L. et al. A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Therapeutic Approaches in the Management of Thyroid Cancer. *Thyroid.* 2021 Jul;31(7):1009-1019. doi: 10.1089/thy.2020.0826. Epub 2021 Jun 23. PMID: 33789450.
34. Haddad R.I., Bischoff L., Ball D., Bernet V., Blomain E., Busaidy N.L., Campbell M., Dickson P. et al. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2022 Aug;20(8):925-951. doi: 10.6004/jnccn.2022.0040. PMID:

35948029.

35. Hamidi S., Hofmann M.C., Iyer P.C., Cabanillas M.E., Hu M.I., Busaidy N.L., Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. *Front Endocrinol (Lausanne)*. 2023 Jun 26;14:1176731. doi: 10.3389/fendo.2023.1176731. PMID: 37435488; PMCID: PMC10331470.

36. Huang M., Yan C., Xiao J., Wang T., Ling R. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. *Diagn Pathol*. 2019 Jul 12;14(1):74. doi: 10.1186/s13000-019-0849-6. PMID: 31300059; PMCID: PMC6626378.

37. Huize Shen, Rui Zhu, Yanyang Liu, Yangjian Hong, Jiaming Ge, Jie Xuan, Wenyuan Niu, Xuefei Yu, Jiang-Jiang Qin, Qinglin Li. Radioiodine-refractory differentiated thyroid cancer: Molecular mechanisms and therapeutic strategies for radioiodine resistance. 2023. 22 october; 72: 101013. doi: 10.1016 / j.drug.2023.101013.

38. Jung C.K., Bychkov A., Kakudo K. Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach. *Endocrinol Metab (Seoul)*. 2022 Oct;37(5):703-718. doi: 10.3803/EnM.2022.1553. Epub 2022 Oct 4. PMID: 36193717; PMCID: PMC9633223

39. Kakudo K., Bychkov A., Bai Y., Li Y., Liu Z., Jung C.K. The new 4th edition World Health Organization classification for thyroid tumors, Asian perspectives. *Pathol Int*. 2018 Dec;68(12):641-664. doi: 10.1111/pin.12737. Epub 2018 Dec 7. PMID: 30537125.

40. Kawasaki K., Kai K., Tanaka N., Kido S., Ibi A., Minesaki A., Yamauchi M., Kuratomi Y., Aishima S., Nakashima M., Ito M. Collision tumor of a papillary and follicular thyroid carcinoma: a case report. *Thyroid Res*. 2023 Aug 7;16(1):24. doi: 10.1186/s13044-023-00167-3. PMID: 37544981; PMCID: PMC10405457.

41. Lavoie H., Gagnon J., Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. *Nat Rev Mol Cell Biol*. 2020 Oct;21(10):607-632. doi: 10.1038/s41580-020-0255-7. Epub 2020 Jun 23. PMID: 32576977.

42. Leboulleux S., Lamartina L., Hadoux J., Baudin E., Schlumberger M. Emerging drugs for the treatment of radioactive iodine refractory papillary thyroid cancer. *Expert Opin Investig Drugs*. 2022 Jul;31(7):669-679. doi: 10.1080/13543784.2022.2071696. Epub 2022 Jul 5. PMID: 35522027.

43. Li G., Lei J., Song L., Jiang K., Wei T., Li Z., Gong R., Zhu J. Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas. *Cancer Med*. 2018 Nov;7(11):5448-5456. doi: 10.1002/cam4.1794. Epub 2018 Sep 27. PMID: 30264548; PMCID: PMC6246937.

44. Liu R., Bishop J., Zhu G., Zhang T., Ladenson P.W., Xing M. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality. *JAMA Oncol*. 2017 Feb 1;3(2):202-208. doi: 10.1001/jamaoncol.2016.3288. PMID: 27581851.

45. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK,

Sun H, El-Naggar AK, Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. *Endocr Relat Cancer*. 2013 Jul 12;20(4):603-10. doi: 10.1530/ERC-13-0210. PMID: 23766237; PMCID: PMC3782569.

46. Liu X., Qu S., Liu R., Sheng C., Shi X., Zhu G., Murugan A.K., Guan H., Yu H., Wang Y., Sun H., Shan Z., Teng W., Xing M. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. *J Clin Endocrinol Metab*. 2014 Jun;99(6):E1130-6. doi: 10.1210/jc.2013-4048. Epub 2014 Mar 11. PMID: 24617711; PMCID: PMC4037723.

47. Luo Y., Jiang H., Xu W., Wang X., Ma B., Liao T., Wang Y. Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review /n/0-d Meta-Analysis. *Front Oncol*. 2020 Sep 30;10:549882. doi: 10.3389/fonc.2020.549882. PMID: 33117686; PMCID: PMC7561400.].

48. Luster M., Aktolun C., Amendeira I., Barczyński M., Bible K.C., Duntas L.H., Elisei R., Handkiewicz-Junak D., Hoffmann M., Jarzab B. et al. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. *Thyroid*. 2019 Jan;29(1):7-26. doi: 10.1089/thy.2017.0129. Epub 2019 Jan 7. PMID: 30484394.

49. Maghsoomi Z, Emami Z, Malboosbaf R, Malek M, Khamseh ME. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. *BMC Cancer*. 2021 May 20;21(1):579. doi: 10.1186/s12885-021-08257-x. PMID: 34016077; PMCID: PMC8139052.

50. Massimino M., Tirrò E., Stella S., Frasca F., Vella V., Sciacca L., Pennisi M.S., Vitale S.R., Puma A., Romano C., Manzella L. Effect of Combined Epigenetic Treatments and Ectopic NIS Expression on Undifferentiated Thyroid Cancer Cells. *Anticancer Res*. 2018 Dec;38(12):6653-6662. doi: 10.21873/anticancer.13032. PMID: 30504373.

51. Melo M., Gaspar da Rocha A., Batista R., Vinagre J., Martins M.J., Costa G., Ribeiro C., Carrilho F., Leite V. et al. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. *J Clin Endocrinol Metab*. 2017 Jun 1;102(6):1898-1907. doi: 10.1210/jc.2016-2785. PMID: 28323937.

52. Mussazhanova Z., Shimamura M., Kurashige T., Ito M., Nakashima M., Nagayama Y. Causative role for defective expression of mitochondria-eating protein in accumulation of mitochondria in thyroid oncocyte cell tumors. *Cancer Sci*. 2020 Aug;111(8):2814-2823. doi: 10.1111/cas.14501. Epub 2020 Jun 30. PMID: 32458504; PMCID: PMC7419045.

53. Mussulmanova M., Targynova A., Mussazhanova Zh., Kaidarova S., Shalgimbayeva G., Mukanova A., Yeleubayeva Zh., Pak L., Bolsynbekova S., Serikbayuly D., Rakhmankulova A., Zhalimbetova Zh., Umirova R., Akhayeveva T., Kurohama H., Nakashima M. BRAF and TERT promoter double mutations in papillary thyroid carcinoma with high-grade features: case report of young patient // *Nauka i Zdravookhranenie [Science & Healthcare]*.

- 2023, (Vol.25) 3, pp. 269-274. doi: 10.34689/SH.2023.25.3.034
54. Na'ara S. et al. Efficacy of posttreatment radioiodine scanning in patients with differentiated thyroid cancer //Head & Neck. – 2019. – T. 41. – №. 9. – C. 3235-3240.
55. Nikiforov Y.E., Nikiforova M.N. Molecular genetics and diagnosis of thyroid cancer. *Nat Rev Endocrinol.* 2011 Aug 30;7(10):569-80. doi: 10.1038/nrendo.2011.142. PMID: 21878896.
56. Paladino S., Melillo R.M. Editorial: Novel Mechanism of Radioactive Iodine Refractivity in Thyroid Cancer. *J Natl Cancer Inst.* 2017 Dec 1;109(12). doi: 10.1093/jnci/djx106. PMID: 30053081.
57. Petranović Ovčariček P., Campenni A., de Keizer B., Deandreis D., Kreissl M.C., Vrachimis A., Tuncel M., Giovanella L. Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer. *Cancers (Basel).* 2023 Aug 27;15(17):4290. doi: 10.3390/cancers15174290. PMID: 37686566; PMCID: PMC10486510.
58. Riesco-Eizaguirre G., Gutiérrez-Martínez P., García-Cabezas M.A., Nistal M., Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na<sup>+</sup>/I<sup>-</sup> targeting to the membrane. *Endocr Relat Cancer.* 2006 Mar;13(1):257-69. doi: 10.1677/erc.1.01119. PMID: 16601293.
59. Sabra M.M., Dominguez J.M., Grewal R.K., Larson S.M., Ghossein R.A., Tuttle R.M., Fagin J.A. Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases, *The Journal of Clinical Endocrinology & Metabolism*, Volume 98, Issue 5, 1 May 2013, Pages E829–E836, <https://doi.org/10.1210/jc.2012-3933>
60. Schlumberger M., Leboulleux S. Current practice in patients with differentiated thyroid cancer. *Nat Rev Endocrinol* 2021;17(3):176–88. DOI: 10.1038/s41574-020-00448-z.
61. Schubert L., Mariko M.L., Clerc J., Huillard O., Groussin L. MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data. *Cancers (Basel).* 2023 Jan 24;15(3):710. doi: 10.3390/cancers15030710. PMID: 36765665; PMCID: PMC9913385.
62. Shen X., Liu R., Xing M. A six-genotype genetic prognostic model for papillary thyroid cancer. *Endocr Relat Cancer.* 2017 Jan;24(1):41-52. doi: 10.1530/ERC-16-0402. Epub 2016 Nov 14. PMID: 27875244; PMCID: PMC5132178.
63. Shobab L., Gomes-Lima C., Zeymo A., Feldman R., Jonklaas J., Wartofsky L., Burman K.D. Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer. *Thyroid.* 2019 Sep;29(9):1262-1268. doi: 10.1089/thy.2019.0075. PMID: 31319763.
64. Sidorin A.V., Abrosimov A.Y., Rogunovich T.I., Rumyantsev P.O., Nizhegorodova K.S., Isaev P.A., Shinkarkina A.P., Yamasita S., Saenko V.A. Klinicheskie, morfologicheskie i prognosticheskie osobennosti papillarnogo raka shchitovidnoi zhelezy s razlichnym statusom BRAF, ustanovlennym immunogistokhimičeskim metodom [Clinical, morphological, and prognostic features of papillary thyroid carcinoma with different BRAF mutational status assessed by immunohistochemistry]. *Arkh Patol.* 2018;80(3):19-25. Russian. doi: 10.17116/patol201880319-25. PMID: 29927436.
65. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PMID: 33538338.
66. Targynova A., Mussazhanova Z., Ueki N., Bolsynbekova S., Yeleubayeva Z., Kalmatayeva Z., Issayeva R., Sarsenova L., Umirova R., Serikbauly D., Nakashima M., Mukanova A.K., Madiyeva M.R. Anaplastic transformation OF BRAF and TERT promoter double mutant papillary thyroid carcinoma: clinical, morphological, and molecular genetic features // *Nauka i Zdravookhranenie [Science & Healthcare]*. 2021. №5. URL: <https://cyberleninka.ru/article/n/anaplastic-transformation-of-braf-and-tert-promoter-double-mutant-papillary-thyroid-carcinoma-clinical-morphological-and-molecular>.
67. Tavares C., Coelho M.J., Eloy C., Melo M., da Rocha A.G., Pestana A., Batista R., Ferreira L.B., Rios E., Selmi-Ruby S., et al. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. *Endocr Connect.* 2018 Jan;7(1):78-90. doi: 10.1530/EC-17-0302. PMID: 29298843; PMCID: PMC5754505.
68. Tavares C., Melo M., Cameselle-Teijeiro J.M., Soares P., Sobrinho-Simões M. Endocrine tumors: Genetic predictors of thyroid cancer outcome. *Eur J Endocrinol.* 2016 Apr;174(4):R117-26. doi: 10.1530/EJE-15-0605. Epub 2015 Oct 28. PMID: 26510840.
69. Tirrò E., Martorana F., Romano C., Vitale S.R., Motta G., Di Gregorio S., Massimino M., Pennisi M.S., Stella S., Puma A., Giani F., Russo M., Manzella L., Vigneri P. Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice. *Genes (Basel).* 2019 Sep 13;10(9):709. doi: 10.3390/genes10090709. PMID: 31540307; PMCID: PMC6771012.
70. Troshina E.A., Mazurina N.V., Abesadze I.A., Yushkov P.V., Yegorycheva Ye.K. Follicular thyroid neoplasia (a lecture). *Problems of Endocrinology.* 2006;52(1):22-25. (In Russ.) <https://doi.org/10.14341/probl200652122-25>
71. Tuttle R.M., Ahuja S., Avram A.M., Bernet V.J., Bourguet P., Daniels G.H., Dillehay G., Draganescu C., Flux G., Führer D. et al. Controversies, Consensus, and Collaboration in the Use of <sup>131</sup>I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging, and the European Thyroid Association. *Thyroid.* 2019 Apr;29(4):461-470. doi: 10.1089/thy.2018.0597. PMID: 30900516.
72. Ueda M., Matsuda K., Kurohama H., Mussazhanova Z., Sailaubekova Y., Kondo H., Shimizu T., Takada N., Matsuoka Y., Otsubo C., Sato S., Yamashita H., Kawakami A., Nakashima M. Molecular Pathological Characteristics of Thyroid Follicular-Patterned Tumors Showing Nodule-in-Nodule Appearance with Poorly Differentiated Component. *Cancers (Basel).* 2022 Jul 22;14(15):3577. doi: 10.3390/cancers14153577. PMID: 35892838; PMCID: PMC9331311.
73. Vaisman F., Carvalho D.P., Vaisman M. A new

appraisal of iodine refractory thyroid cancer. *Endocr Relat Cancer*. 2015 Dec;22(6):R301-10. doi: 10.1530/ERC-15-0300. Epub 2015 Aug 25. PMID: 26307020.

74. Van Nostrand D. The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer. *Thyroid*. 2009 Dec;19(12):1381-91. doi: 10.1089/thy.2009.1611. PMID: 20001720.

75. Vasil'ev E.V., Rumiantsev P.O., Saenko V.A., Il'in A.A., Poliakov E.I., Nemtsova M.V., Zaletov D.V. Molekuliarnyi analiz strukturnykh narushenii genoma papilliarnykh kartsinom shchitovidnoi zhelezy [Molecular analysis of structural abnormalities in papillary thyroid carcinoma gene]. *Mol Biol (Mosk)*. 2004 Jul-Aug;38(4):642-53. Russian. PMID: 15456136.

76. Vella V., Malaguamera R. The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives. *Int J Mol Sci*. 2018 Nov 30;19(12):3814. doi: 10.3390/ijms19123814. PMID: 30513575; PMCID: PMC6321330.

77. Vitale G., Pellegrino G., Desiderio E., Barrea L. Radioiodine-refractory thyroid cancer: a complex challenge. *Minerva Med*. 2021 Dec;112(6):686-688. doi: 10.23736/S0026-4806.21.07845-9. Epub 2021 Oct 21. PMID: 34672171.

78. Vuong H.G., Altibi A.M.A., Duong U.N.P., Hassell L. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. *Clin Endocrinol (Oxf)*. 2017 Nov;87(5):411-417. doi: 10.1111/cen.13413. Epub 2017 Aug 2. PMID: 28666074.

79. Wassermann J., Bernier M.O., Spano J.P., Lepoutre-Lussey C., Buffet C., Simon J.M., Ménégau F., Tissier F., Leban M., Leenhardt L. Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas. *Oncologist*. 2016 Jan;21(1):50-8. doi: 10.1634/theoncologist.2015-0107. Epub 2015 Dec 16. PMID: 26675742; PMCID: PMC4709201.

80. Xing M., Liu R., Liu X., Murugan A.K., Zhu G., Zeiger M.A., Pai S., Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. *J Clin Oncol*. 2014 Sep 1;32(25):2718-26. doi: 10.1200/JCO.2014.55.5094. Epub 2014 Jul 14. PMID: 25024077; PMCID: PMC4145183.

81. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. *Endocr Rev*. 2007 Dec;28(7):742-62. doi: 10.1210/er.2007-0007. Epub 2007 Oct 16. PMID: 17940185.

82. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. *Nat Rev Cancer*. 2013 Mar;13(3):184-99. doi: 10.1038/nrc3431. PMID: 23429735; PMCID: PMC3791171.

83. Yang X., Li J., Li X., Liang Z., Gao W., Liang J., Cheng S., Lin Y. TERT Promoter Mutation Predicts Radioiodine-Refractory Character in Distant Metastatic Differentiated Thyroid Cancer. *J Nucl Med*. 2017 Feb;58(2):258-265. doi: 10.2967/jnumed.116.180240. Epub 2016 Aug 4. PMID: 27493271.

84. Yavuz S., Puckett Y. Iodine-131 Uptake Study. 2023 Oct 29. In: *StatPearls* [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 32644709.

85. Yoo S.K., Lee S., Kim S.J., Jee H.G., Kim B.A., Cho

H., Song Y.S., Cho S.W., Won J.K., Shin J.Y. et al. Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. *PLoS Genet*. 2016 Aug 5;12(8):e1006239. doi: 10.1371/journal.pgen.1006239. PMID: 27494611; PMCID: PMC4975456.

86. Yu J, Liu Z, Su Y, Peng X, Xie Y. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis. *Clin Endocrinol (Oxf)*. 2024 Apr;100(4):379-388. doi: 10.1111/cen.15027. Epub 2024 Feb 13. PMID: 38351437.

87. Yujia Liu, Jiafeng Wang, Xiaoping Hu, Zongfu Pan, Tong Xu, Jiajie Xu, Liehao Jiang, Ping Huang, Yiwen Zhang, Minghua G. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy, *Drug Resistance Updates*, Volume 68, 2023, 100939, ISSN 1368-7646, <https://doi.org/10.1016/j.drug.2023.100939>.

88. Zhang Y., Wu Q.L., Yun J.P. [Interpretation of the fourth edition of WHO pathological classification of the thyroid tumors in 2017]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi*. 2018 Sep 7;53(9):718-720. Chinese. doi: 10.3760/cma.j.issn.1673-0860.2018.09.020. PMID: 30293272.

89. Zheng X., Xu Z., Ji Q., Ge M., Shi F., Qin J., Wang F., Chen G., Zhang Y., Huang R., et al. A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer. *Clin Cancer Res*. 2021 Oct 15;27(20):5502-5509. doi: 10.1158/1078-0432.CCR-21-0761. Epub 2021 Jul 29. PMID: 34326132; PMCID: PMC9401493

#### References:

1. Abdrashitova A.T., Panova T.N., D'yakova O.N., Dzhuvalyakov S.G., Teplyi D.L. Podkhody k rannei diagnostike raka shchitovidnoi zhelezy [Approaches to early diagnosis of thyroid cancer]. *Kubanskii nauchnyi meditsinskii vestnik zhelezy* [Kuban Scientific Medical bulletin]. 2018. 25(3):139-148. [in Russian]

2. Amirov E.V., Fedorov V.E., Zahohov R.M. Rezul'taty hirurgicheskogo lecheniya uzlovykh obrazovaniy shchitovidnoj zhelezy u zhenshchin reproduktivnogo vozrasta [Results of surgical treatment of thyroid nodules in women of reproductive age] // *Meditsinskij al'manah* [Medical almanac]. 2013. №6 (30). S. 184-186. [in Russian]

3. Bel'tsevich D.G., Mudunov A.M., Vanushko V.E., Rummyantsev P.O., Mel'nichenko G.A., Kuznetsov N.S., Podvyaznikov S.O., Alymov Yu.V. i dr. Differentsirovannyi rak shchitovidnoi zhelezy [Differentiated thyroid cancer]. *Sovremennaya onkologiya* [Modern oncology]. 2020. T. 22. №4. pp. 30-44. doi: 10.26442/18151434.2020.4.200507 [in Russian]

4. Borodavina E.V., Krylov V.V., Isaev P.A., Shurinov A.Yu., Rodichev A.A. (Ne na meste) Istoricheskie aspekty i sovremennye kontseptsii v lechenii bol'nykh differentsirovannykh rakom shchitovidnoi zhelezy, refrakternym k terapii radioaktivnym iodom [Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer refractory to radioactive iodine therapy]. *Opukholi golovy i shei* [Head and Neck Tumors]. 2021. T.11. №.4. p. 119-130. [in Russian]

5 Garipov K. A., Afanas'eva Z. A., Gafiullina A. D. Rol'

apoptoza v formirovani radiojodrezistentnosti pri differencirovannom rake shchitovidnoj zhelezy [The role of apoptosis in the formation of radioiodine resistance in differentiated thyroid cancer] //Vestnik Avicenny [Avicenna Bulletin]. – 2020. – T. 22. – №. 2. – S. 301-310. [in Russian]

6. Denisenko N.P., Shuev G.N., Mukhamadiev R.Kh., Perfil'eva O.M., Kazakov R.E., Kachanova A.A., Milyutina O.I., Konenkova O.V. i dr. Geneticheskie markery, assotsiirovannye s rezistentnost'yu k radioiodterapii, u bol'nykh rakom shchitovidnoj zhelezy [Genetic markers associated with resistance to radioiodine therapy in patients with thyroid cancer]. *Sovremennaya onkologiya* [Modern Oncology]. 2022. T.24. №.3. pp. 345-350. [in Russian]

7. Ponkina O.N. Klassifikatsiya opukholei shchitovidnoj zhelezy (VOZ, 2017): aktsent na prognoz [Emphasis on prognosis]. *Innovatsionnaya meditsina Kubani* [Innovative medicine of Kuban]. 2017. T.8. №4. pp. 53-59. URL: <https://cyberleninka.ru/article/n/klassifikatsiya-opukholei-shchitovidnoj-zhelezy-voz-2017-aktsent-na-prognoz> (data obrashcheniya: 29.03.2023). [in Russian]

8. Romashchenko P.N., Maistrenko N.A., Krivolapov D.S., Simonova M.S. Molekulyarno-geneticheskie issledovaniya v khirurgii shchitovidnoj zhelezy [Molecular genetic studies in thyroid surgery]. *Tavrisheskii mediko-biologicheskii vestnik* [Tauride Medical and Biological Bulletin]. 2021. T. 24. №2. pp.118-126. URL: <https://cyberleninka.ru/article/n/molekulyarno-geneticheskie>

issledovaniya-v-hirurgii-schitovidnoy-zhelezy. [in Russian]

9. Rumyantsev P.O., Nikiforovich P.A., Poloznikov A.A., Abrosimov A.Yu., Saenko V.A., Rogunovich T.I., Budzin A.A., Polyakov A.P., i dr. Mutatsiya BRAFV600E pri papillyarnom rake shchitovidnoj zhelezy. Klinicheskie i metodologicheskie aspekty [BRAFV600E mutation in papillary thyroid cancer. Clinical and methodological aspects]. *Voprosy onkologii* [Issues of oncology]. 2019. T.65. No.1. pp.16-26. [in Russian]

10. Shurinov A.Yu., Krylov V.V., Borodavina E.V. Radioiodablatsiya pri rake shchitovidnoj zhelezy. Istoricheskie i sovremennye aspekty. Obzor literatury [Radioiodine ablation for thyroid cancer. Historical and modern aspects. Literature review]. *Onkologicheskii zhurnal: luchelevaya diagnostika, luchelevaya terapiya* [Oncological journal: radiation diagnostics, radiation therapy]. 2021. T. 4. №. 4. pp.9-19. [in Russian]

11. Shurinov A.Yu., Borodavina E.V. Dinamicheskii kontrol' posle radioiodablyatsii pri differentsirovannom rake shchitovidnoj zhelezy: vzglyad radiologa [Dynamic control after radioiodine ablation for differentiated thyroid cancer: a radiologist's view]. *Opukholi golovy i shei* [Head and Neck Tumors]. 2023. T.13. No.1. pp. 91-101. URL: <https://cyberleninka.ru/article/n/dinamicheskii-kontrol-posle-radioiodablyatsii-pri-differentsirovannom-rake-schitovidnoy-zhelezy-vzglyad-radiologa>. [in Russian]

#### Information about authors:

<sup>1</sup> **Rakhmankulova Aidana Manarovna** – a PhD student of the Department of Clinical Oncology and Nuclear Medicine, num:87783398242, e-mail:[dana77792@mail.ru](mailto:dana77792@mail.ru), <https://orcid.org/0000-0003-3307-413X>, NCJSC "Semey Medical University," Semey, Republic of Kazakhstan;

<sup>1</sup> **Pak Laura Alekseevna** – PhD, Associate Professor, Head of the Department of Clinical Oncology and Nuclear Medicine named after Prof. D.R.Musinova, num: 87071011393, e-mail: [laura\\_pak@mail.ru](mailto:laura_pak@mail.ru), <https://orcid.org/0000-0002-5249-3359>, NCJSC "Semey Medical University," Semey, Republic of Kazakhstan;

<sup>1</sup> **Pivina Lyudmila Mikhailovna** – Candidate of Medical Sciences, Professor, NJSC «Semey Medical University», Professor of the Department of Emergency Medicine named after. professor Corresponding Member of NAEN, num:87055227300; e-mail: [semekluda@rambler.ru](mailto:semekluda@rambler.ru); <https://orcid.org/0000-0002-8035-4866>, Semey, Republic of Kazakhstan;

<sup>2</sup> **Tanatarov Sayat Zamambekovich** – Doctor of Medical Sciences, Acting Director of the Center for Nuclear Medicine and Oncology, num: 87056517959; <https://orcid.org/0000-0001-8958-8768>; Semey, Republic of Kazakhstan;

<sup>2</sup> **Atantaeva Bayan Zhumagazyevna** - Candidate of Medical Sciences, Head of the Department of Radionuclide Therapy, Center for Nuclear Medicine and Oncology, num:+77772964797; e-mail:[bayan\\_atantaeva@mail.ru](mailto:bayan_atantaeva@mail.ru); <https://orcid.org/0009-0003-0004-8354>; Semey, Republic of Kazakhstan;

<sup>1</sup> **Mussulmanova Madina Aziyatovna** - Assistant at the Department of Clinical Oncology and Nuclear Medicine named after prof. D.R.Musinova, Semey Medical University, num:87076594056; e-mail:[87madina87@mail.ru](mailto:87madina87@mail.ru); <https://orcid.org/0009-0006-5557-3692>; Semey, Republic of Kazakhstan;

<sup>3</sup> **Bolsynbekova Saltanat Orazgalievna** - Head of the Center for Pathomorphology with Cytology; National Scientific Cancer Center; num: 87772734010; e-mail:[salta72.72@mail.ru](mailto:salta72.72@mail.ru); орқид: <https://orcid.org/0009-0002-2462-1883> r. Astana, Republic of Kazakhstan;

<sup>4</sup> **Kabildina Nailya Amirbekovna** - Associate Professor, Candidate of Medical Sciences, Head. Department of Oncology and Radiation Diagnostics of NJSC "Medical University of Karaganda"; num: 87015338259; e-mail: [nailyakabildina@mail.ru](mailto:nailyakabildina@mail.ru); <https://orcid.org/0000-0002-5616-1829>; Karaganda, Republic of Kazakhstan.

<sup>2</sup> **Baurzhan Arailym Baurzhankyzy** – PhD Doctor, sonologist of the Center for Nuclear Medicine and Oncology, num: 87755378239, e-mail:[Aiko\\_-\\_87@mail.ru](mailto:Aiko_-_87@mail.ru); <https://orcid.org/0000-0003-0279-6607>; Semey, Republic of Kazakhstan.

#### Corresponding author:

**Rakhmankulova A.M.** - a Ph.D. student of the Department of Clinical Oncology and Nuclear Medicine, NCJSC "Semey Medical University," Semey, Republic of Kazakhstan

**Postal address:** 071400, Republic of Kazakhstan, Semey, Abay Street, 103.

**E-mail:** [dana77792@mail.ru](mailto:dana77792@mail.ru)

**Phone:** 87783398242